This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Double Blind Crossover Trial of Levetiracetam (Keppra®) and Placebo in the Treatment of Restless Legs Syndrome (RLS)

This study has been completed.
UCB Pharma
Information provided by:
Sleep Health Centers Identifier:
First received: October 28, 2005
Last updated: NA
Last verified: October 2005
History: No changes posted
To define the effective dose and tolerability of levetiracetam in individuals with Restless Legs Syndrome (RLS). It is hypothesized that levetiracetam will be well tolerated, safe and effective in treating the symptoms of RLS.

Condition Intervention Phase
Restless Legs Syndrome Drug: Levetiracetam (Keppra) Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A Double Blind Crossover Trial of Levetiracetam (Keppra®) and Placebo in the Treatment of Restless Legs Syndrome (RLS)

Resource links provided by NLM:

Further study details as provided by Sleep Health Centers:

Primary Outcome Measures:
  • 1:To investigate the efficacy of levetiracetam when used to treat RLS.
  • 2:To assess tolerability and adverse event rates.

Estimated Enrollment: 20
Study Start Date: November 2003
Estimated Study Completion Date: October 2005

Ages Eligible for Study:   18 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosed with idiopathic RLS according to the four IRLSSG diagnostic criteria

    1. An urge to move the legs, usually accompanied or caused by uncomfortable and unpleasant sensations in the legs.
    2. The urge to move or unpleasant sensations begin or worsen during periods of rest or inactivity such as sitting or lying down.
    3. The urge to move or unpleasant sensations are partially or totally relieved by movement, such as walking or stretching, at least as long as the activity continues
    4. The urge to move or unpleasant sensations are worse in the evening or night than during the day or only occur in the evening or night.

IRLS Rating Scale score greater than 15 at Baseline visit PLM-Index of 5 or greater during the first night of polysomnography Written informed consent obtained prior to any study procedures being performed.

Exclusion Criteria:

  1. Women of childbearing potential, who have a positive urine pregnancy test or are lactating as the screening visit, or do not practice a clinically accepted method of contraception.
  2. Individuals who are taking medication for Restless Legs Syndrome without a proper washout period
  3. Individuals who are taking hypnotics, sedatives, antipsychotics, or neuroleptics
  4. History of current diagnosis of other clinically relevant diseases that may confound assessments of RLS symptoms (e.g., Parkinson’s disease, dementia, ALS, etc.)
  5. Subjects with serum ferritin below 10µg/L
  6. Subjects with an untreated sleep disorder that may confound assessments (e.g., narcolepsy, sleep apnea syndrome or other breathing-related sleep disorders, or REM sleep behaviour disorder)
  7. Subjects with an apnea/hypopnea index of 15 or greater at the initial polysomnography visit
  8. Subjects employed in shift work (e.g., employment hours disruptive to the normal circadian sleep-wake cycle such as nighttime or variable rotating shifts)
  9. Subjects who have clinically significant or unstable medical conditions which in the opinion of the investigator would render the subject unsuitable for the study (e.g. severe cardiovascular disease, major depression, psychosis, hepatic or renal failure, etc.)
  10. subjects with a positive urine drug test for illicit use of amphetamines, barbiturates, benzodiazepines, opiates, synthetic narcotics, and miscellaneous drugs commonly known as recreational drugs (e.g., cannabinoids including THC, heroine, cocaine)
  11. Participation in any clinical drug or device trial in the 30 days prior to the screening visit.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00247364

United States, Massachusetts
Sleep Health Centers
Newton, Massachusetts, United States, 02459
Sponsors and Collaborators
Sleep Health Centers
UCB Pharma
Principal Investigator: John W Winkelman, MD, PhD Sleep Health Centers, Brigham and Women's Hosptial
  More Information Identifier: NCT00247364     History of Changes
Other Study ID Numbers: 2003-P-001804
Study First Received: October 28, 2005
Last Updated: October 28, 2005

Keywords provided by Sleep Health Centers:

Additional relevant MeSH terms:
Restless Legs Syndrome
Psychomotor Agitation
Pathologic Processes
Neurologic Manifestations
Nervous System Diseases
Psychomotor Disorders
Neurobehavioral Manifestations
Signs and Symptoms
Sleep Disorders, Intrinsic
Sleep Wake Disorders
Mental Disorders
Nootropic Agents
Neuroprotective Agents
Protective Agents
Physiological Effects of Drugs processed this record on August 18, 2017